| Title |
Emerging treatment options for nasopharyngeal carcinoma
|
|---|---|
| Published in |
Drug Design, Development and Therapy, February 2013
|
| DOI | 10.2147/dddt.s30753 |
| Pubmed ID | |
| Authors |
Lu Zhang, Qiu-Yan Chen, Huai Liu, Lin-Quan Tang, Hai-Qiang Mai |
| Abstract |
Nasopharyngeal carcinoma is endemic in Asia and is etiologically associated with Epstein-Barr virus. Radiotherapy is the primary treatment modality. The role of systemic therapy has become more prominent. Based on multiple phase III studies and meta-analyses, concurrent cisplatin-based chemoradiotherapy is the current standard of care for locally advanced disease (American Joint Committee on Cancer manual [7th edition] stages II-IVb). The reported failure-free survival rates from phase II trials are encouraging for induction + concurrent chemoradiotherapy. Data from ongoing phase III trials comparing induction + concurrent chemoradiotherapy with concurrent chemoradiotherapy will validate the results of these phase II studies. Intensity-modulated radiotherapy techniques are recommended if the resources are available. Locoregional control exceeding 90% and reduced xerostomia-related toxicities can now be achieved using intensity-modulated radiotherapy, although distant control remains the most pressing research problem. The promising results of targeted therapy and Epstein-Barr virus-specific immunotherapy from early clinical trials should be validated in phase III clinical trials. New technology, more effective and less toxic chemotherapy regimens, and targeted therapy offer new opportunities for treating nasopharyngeal carcinoma. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Venezuela, Bolivarian Republic of | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | <1% |
| Unknown | 104 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 15% |
| Student > Master | 15 | 14% |
| Other | 9 | 9% |
| Researcher | 9 | 9% |
| Student > Postgraduate | 9 | 9% |
| Other | 25 | 24% |
| Unknown | 22 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 45% |
| Agricultural and Biological Sciences | 10 | 10% |
| Biochemistry, Genetics and Molecular Biology | 9 | 9% |
| Nursing and Health Professions | 7 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Other | 8 | 8% |
| Unknown | 22 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 August 2016.
All research outputs
#19,944,091
of 25,373,627 outputs
Outputs from Drug Design, Development and Therapy
#1,310
of 2,268 outputs
Outputs of similar age
#221,855
of 291,207 outputs
Outputs of similar age from Drug Design, Development and Therapy
#11
of 22 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,207 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.